LDLR and COVID-19: In the absence of a validated small animal model of COVID-19 lung disease36 and the urgent need for relevant preclinical data, we used the well-characterized bleomycin model to undertake pragmatic studies that we hope will provide useful data for clinicians developing early phase studies of LDLR in patients with COVID-19.